Other ways to assess RP

Article

Metrics other than visual acuity (VA) and visual field (VF) may be useful for assessing retinitis pigmentosa (RP), according to study results published in the February issue of Eye.

Metrics other than visual acuity (VA) and visual field (VF) may be useful for assessing retinitis pigmentosa (RP), according to study results published in the February issue of Eye.

H Nakamura, of the Department of Ophthalmology and Visual Sciences at Kyoto University Graduate School of Medicine, Japan, and colleagues conducted a cross-sectional observational study evaluating the foveal and macular function of three groups of RP patients (n=56), which they assessed using optical coherence tomography (OCT) and focal electroretinogram (fERG) as well as VA and VF tests. The groups were divided as follows: those with no photoreceptor inner/outer segment junction (IS/OS) visible on OCT (Group 1, n=22); those with IS/OS of ≤2 mm (Group 2, n=18), and those with >2 mm IS/OS (Group 3, n=16).

Group 1 patients showed non-recordable fERG and a significantly lower average VA than Group 2 and 3 patients, who had similar VA scores and, on the whole, demonstrated recordable fERG amplitudes. The differences between the amplitudes registered by each group differed significantly, although no implicit time differences between Groups 2 and 3 were shown.

The researchers therefore concluded that, in addition to the traditional VA and VF analysis, fERG amplitudes and an OCT analysis of the IS/OS may aid in assessing foveal and macular function in RP.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.